0.73
+0.0175(+2.47%)
Currency In USD
| Previous Close | 0.71 |
| Open | 0.71 |
| Day High | 0.73 |
| Day Low | 0.71 |
| 52-Week High | 6.07 |
| 52-Week Low | 0.65 |
| Volume | 70,809 |
| Average Volume | 131,173 |
| Market Cap | 5.41M |
| PE | -0.1 |
| EPS | -7.13 |
| Moving Average 50 Days | 0.74 |
| Moving Average 200 Days | 1.32 |
| Change | 0.02 |
If you invested $1000 in Pasithea Therapeutics Corp. (KTTA) since IPO date, it would be worth $10.22 as of September 29, 2025 at a share price of $0.727. Whereas If you bought $1000 worth of Pasithea Therapeutics Corp. (KTTA) shares 3 years ago, it would be worth $30.82 as of September 29, 2025 at a share price of $0.727.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
GlobeNewswire Inc.
Sep 16, 2025 11:03 AM GMT
First patient in South Korea dosedMIAMI, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhib
Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
GlobeNewswire Inc.
Sep 08, 2025 11:01 AM GMT
-- Recommendation that trial escalate to next dose level of 8mg tablet -- -- Initial interim clinical data from first two cohorts expected in Q1 2026 -- MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea
Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Aug 29, 2025 12:39 PM GMT
MIAMI, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced change of dat